Riskpilot← Back to searchSign inGet full accessNovo Nordisk Research Center Gladsaxe ApS
APSActiveCVR 39119374Novo Alle 1Research and experimental development on natural sciences and engineering · NACE 7210Est. 20177 employees
Revenue 2024
DKK -38K
EBITDA margin
100.0%
-100% vs 2023
Equity ratio
79.5%
Financial strength
Net profit 2024
DKK 6,2M
-98% vs 2023
| Revenue | DKK -38K | — |
| EBITDA | DKK -38K | -100% |
| Net profit | DKK 6,2M | -98% |
| Total assets | DKK 8,5M | -98% |
| Equity | DKK 6,8M | -98% |
| Employees | 7 | — |
Legal name
Novo Nordisk Research Center Gladsaxe ApS
CVR number
39119374
Legal form
Anpartsselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
28. november 2017
Share capital
DKK 51.515
Employees
7 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af 2 bestyrelsesmedlemmer i forening eller af et bestyrelsesmedlem i forening med en direktør.
Company purpose
Selskabets formål er at udføre forskning, udvikling og støtte kliniske forsøg af farmaceutiske produkter og at markedsføre, promovere, sælge og distribuere farmaceutiske og medicinske produkter samt enhver anden aktivitet i forbindelse hermed. Endvidere er selskabets formål at understøtte Novo Nordisk A/S' farmaceutiske aktiviteter. Selskabet bestræber sig på at udføre sine aktiviteter på en økonomisk, miljømæssig og socialt ansvarlig måde.
Address
Novo Alle 1
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenue | 14.947 | 25.624 | 10.677 | 0 | 379 | — | -38 |
| Staff expenses | -977 | -4.811 | -4.427 | -3.304 | -3.696 | -0 | -0 |
| EBITDA | 12.601 | 18.554 | 4.795 | -6.694 | -6.282 | 514.764 | -38 |
| Depreciation & amort. | -0 | -0 | -718 | -690 | -1.521 | -0 | -0 |
| EBIT | 12.601 | 18.554 | 4.077 | -7.384 | -7.803 | 514.764 | -38 |
| Net financials | -11 | -52 | -159 | -489 | -3.450 | -9.414 | 7.953 |
| Profit before tax | 12.590 | 18.501 | 3.918 | -7.682 | -9.983 | 507.557 | 7.915 |
| Tax | 2.770 | 4.075 | 733 | -1.486 | -1.153 | 111.353 | 1.741 |
| Net profit | 9.821 | 14.426 | 3.185 | -6.196 | -8.830 | 395.475 | 6.174 |
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Total assets | 12.529 | 28.231 | 11.705 | 10.693 | 7.777 | 516.988 | 8.506 |
| Equity | 9.876 | 18.302 | 9.487 | 2.941 | -5.889 | 405.585 | 6.759 |
| Long-term debt | 0 | 170 | 487 | 5.806 | 9.096 | 0 | 0 |
| Short-term debt | 2.653 | 9.758 | 1.587 | 1.947 | 4.570 | 111.403 | 1.747 |
| Total debt | 2.653 | 9.928 | 2.074 | 7.752 | 13.666 | 111.403 | 1.747 |
EBITDA margin
-3800000.0%
This company
15.8%
Market median
-24050733% vs market
20182024
Equity ratio
79.5%
This company
38.2%
Market median
+108% vs market
20182024
Return on equity
91.3%
This company
18.4%
Market median
+396% vs market
20182024
Net profit margin
617400000.0%
This company
8.1%
Market median
+7622222122% vs market
20182024
Asset turnover
-0.00×
This company
1.12×
Market median
-100% vs market
20182024
Debt / equity
0.26×
This company
0.62×
Market median
+58% vs market
20182024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2017-11-28 – 2018-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
CT Chief Executive Officer | Chief Executive Officer | 2017 | — | — |
JB Management | Management | 2021 | — | — |
TH Management | Management | 2023 | — | — |
RR Chief Executive Officer | Chief Executive Officer | 2025 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2021 | — | — | |
| Board of Directors | 2023 | — | — | |
| Chairman | 2023 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
NOVO NORDISK A/S | Company | 100.0% | 100.0% | 2023 |
Gerhart-Hines Holding ApS | Company | 25.0% | 25.0% | 2017 |
Embark Holdings ApS | Company | 90.0% | 90.0% | 2023 |
Bondo Hansen Holding ApS | Company | 25.0% | 25.0% | 2017 |
Receptor Holding ApS | Company | 25.0% | 25.0% | 2017 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
NOVO NORDISK FONDENNovo Holdings A/SNOVO NORDISK A/S
Novo Nordisk Research Center Gladsaxe ApS (this company)Board members of Novo Nordisk Research Center Gladsaxe ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Casper Tind Hansen | Chief Executive Officer | 0 companies |
| Jakob Bondo Hansen | Management | 0 companies |
| Trine Haastrup | Management | 0 companies |
| Rikke Ryttergaard Andersen | Chief Executive Officer | 0 companies |
| Klaus Christian Schollmeier | Chairman | 0 companies |
| Kristine Aachmann Bethe | Board of Directors | 0 companies |
| Peter Bøggild | Chairman | 0 companies |